查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006478

人源化小鼠和大鼠模型市場：按模型類型、應用、最終用戶和人類細胞分類－2026-2032年全球市場預測

Humanized Mouse & Rat Model Market by Model Type, Application, End User, Human Cell - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人源化小鼠和大鼠模型市場價值將達到 2.9724 億美元，到 2026 年將成長至 3.1757 億美元，到 2032 年將達到 4.9448 億美元，複合年成長率為 7.54%。

主要市場統計數據
基準年 2025 2.9724億美元
預計年份：2026年 3.1757億美元
預測年份 2032 4.9448億美元
複合年成長率 (%) 7.54%

專家概述了人源化小鼠和大鼠模型的創新如何改變前臨床開發平臺和轉化研究重點。

人源化小鼠和大鼠模型已成為現代非臨床研究中不可或缺的工具，為免疫學、感染疾病、腫瘤學、神經病學和心血管科學等領域的轉化研究提供了重要依據。這些基因改造和患者來源的模型系統透過提供生理適宜的環境，日益彌合體外研究結果與臨床現實之間的差距，從而檢驗人類特異性免疫相互作用、病原體親和性和腫瘤生物學特性。隨著實驗目標的日益複雜，研究人員和產品開發人員需要更高保真度的模型、更可靠的表徵手段和更完善的服務，以縮短獲得可操作資料的時間並提高實驗結果的可重複性。

基因組工程、PDX（患者衍生模型）能力和綜合服務交付的進步如何重新定義轉化價值和實驗可重複性。

由於技術、操作和科學領域各方力量的融合，人源化囓齒動物模型的格局正在經歷一場變化。首先，精準的基因組工程和先進的免疫移植技術提高了人源化免疫系統和器官特異性表現型的保真度，從而能夠更準確地評估免疫療法和生物製藥的療效。同時，患者來源的異質骨移植庫的擴充以及冷凍保存技術的進步，維持了腫瘤的異質性和臨床相關性，加速了轉化腫瘤學計畫的進展。

本研究評估了 2025 年關稅調整將如何影響臨床前研究生態系統內的供應彈性、籌資策略和供應商多元化。

一系列於2025年前後實施的政策調整和關稅措施，對依賴專業動物模型及相關實驗室材料的機構的供應鏈和產業計畫產生了多方面的影響。對許多終端用戶而言，最直接的影響是進口種畜、專用耗材和某些試劑的到貨成本增加，促使採購團隊與供應商重新談判合約、合併訂單，並優先選擇製造地分佈在各地的供應商。作為應對措施，一些供應商已採取相應措施，例如轉移關鍵生產過程、盡可能提高國內繁殖能力以及擴大本地庫存，以應對更長的前置作業時間週期。

詳細的細分分析揭示了模型類型、應用重點、最終用戶優先順序和產品/服務配置如何影響採購和研發選擇。

透過按模型類型、應用、最終用戶和產品類型分析人源化囓齒動物市場格局，可以為研發規劃人員和採購經理提供具體的策略見解。按模型類型分類，該市場包括人源化大鼠模型、免疫力缺乏模型、PDX模型和基因轉殖模型。人源化大鼠模型類別包括hACE2和hCD4大鼠模型，它們分別在病毒親和性研究和免疫腫瘤學研究中特別重要。免疫力缺乏模型進一步包括NOG、NSG和SCID模型，這些模型在移植效率、免疫表現型以及對不同異種移植和人體免疫系統重建工作流程的適用性方面存在差異。患者來源的異種移植模型包括乳癌PDX、大腸直腸癌PDX和肺癌PDX，它們提供疾病特異性的保真度，以支持治療假設檢驗和生物標記發現。基因改造模型用於機制闡明和標靶檢驗，包括基因敲入模型和基因敲除模型，每種模型在基因功能和路徑調控研究中都具有獨特的優勢。

這項區域比較分析詳細說明了美洲、歐洲、中東和非洲以及亞太地區各區域的優勢如何影響模型採購、合規性和服務採用。

區域趨勢正以不同的方式影響人源化囓齒動物模型的供應能力、調節合作和應用軌跡。美洲地區生物技術中心集中，擁有強大的轉化研發管線和成熟的合約研究產業，因此對先進的人源化模型和PDX平台的採用率很高。該地區受益於完善的實驗室基礎設施和強大的服務供應商網路，這共同降低了進入複雜體內研究計畫的門檻，但也面臨著與人事費用和監管合規相關的成本壓力。相較之下，歐洲、中東和非洲地區呈現異質性格局，傑出的學術機構和專業服務提供者與不同的監管和報銷環境並存。這種多樣性為跨境合作和專業化細分市場服務創造了機會，但也需要仔細考慮不同的動物福利標準和進出口法規。

深入了解決定臨床前服務競爭優勢的供應商策略、服務整合、專有模型開發和夥伴關係。

供應商與服務供應商之間的競爭格局呈現出專業化與整合並存的態勢，各公司都在追求垂直整合、專有模型庫和加值服務包。領先的供應商正增加對冷凍保存的PDX庫、先進的表現型分析平台和專有的人源化通訊協定的投資，以確保與客戶建立長期合作關係，並在技術上脫穎而出。同時，合約研究組織（CRO）正透過策略合作、資本投資和擴大符合GLP規範的設施，拓展其體內研究能力，以支持後期治療計畫。

領導者應採取切實可行的策略步驟來增強供應商的韌性、轉化有效性、監管應對力和服務整合能力。

在不斷發展的人源化囓齒動物生態系統中，產業領導者可以採取一系列切實可行的措施來增強營運韌性、科學嚴謹性和商業性地位。首先，應優先考慮供應商合格流程，包括記錄繁殖記錄、基因檢驗和移植性能，並將這些標準納入長期採購契約，從而降低變異性。其次，對於關鍵模型和試劑，應投資雙源採購策略和區域冗餘，以減輕政策變化和物流限制帶來的干擾，並確保研究進度不受影響。

我們採用透明、多方面的研究途徑，結合專家訪談、文件分析和檢驗檢查，為相關人員。

本分析的調查方法結合了結構化的初步研究、嚴謹的二手資料審查和迭代檢驗，確保了研究結果的穩健性和實用性。初步資訊透過訪談科學研究負責人、採購經理和合約研究機構（CRO）高階主管收集，以了解實際決策標準、對前置作業時間的敏感度以及對不斷變化的服務的期望。二手資料研究涵蓋了同行評審文獻、監管指導文件、產品技術文件和營運報告，以揭示技術進步和品質標準。這些定性資訊和文獻資料被整合起來，用於建立細分框架、供應鏈影響情境分析以及跨區域比較評估。

最終的整合突顯了科學準確性、供應商合格和營運彈性的整合對於轉化研究的成功至關重要。

總之，人源化小鼠和大鼠模型是連結實驗生物學和臨床應用的關鍵橋樑，基因工程、PDX模型保存和綜合服務交付的持續創新正在重新定義臨床前策略。在技​​術進步、監管預期和供應鏈趨勢相互作用的背景下，申辦者必須採取更精細的採購、合格和合作方式。隨著關稅和政策環境的演變，投資於供應商多元化、嚴格的文件記錄和轉化檢測整合的機構將更有利於保持專案進展勢頭，並從體內試驗中獲得更大的預測價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依模型類型分類的人源化小鼠和大鼠模型市場

  • 人源化大鼠模型
    • hACE2 大鼠模型
    • hCD4 大鼠模型
  • 免疫力缺乏模型
    • NOG模型
    • NSG模型
    • SCID模型
  • PDX 型號
    • 乳癌PDX
    • 結腸癌PDX
    • 肺癌PDX
  • 基因改造模型
    • 敲入式模型
    • 淘汰賽模特兒

第9章：人源化小鼠與大鼠模型市場：依應用分類

  • 心血管系統
    • 動脈粥狀硬化模型
    • 高血壓模型
  • 免疫學
    • 自體免疫疾病模型
    • 發炎性疾病模型
  • 感染疾病
    • 細菌感染模型
    • 病毒感染模型
  • 腫瘤學
  • 細胞療法試驗

第10章：人源化小鼠與大鼠模型市場：依最終使用者分類

  • 學術研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第11章 依人類細胞類型分類的人源化小鼠和大鼠模型市場

  • CD34+幹細胞
  • PBMC
  • 患者來源的腫瘤組織（PDX）
  • 誘導性多能幹細胞衍生細胞

第12章：人源化小鼠與大鼠模型市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人源化小鼠與大鼠模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人源化小鼠與大鼠模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人源化小鼠與大鼠模型市場

第16章：中國人源化小鼠與大鼠模型市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aragen Life Sciences Ltd.
  • Biocytogen
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Crown Biosciences
  • Cyagen Biosciences
  • GemPharmatech
  • genOway
  • Harbour BioMed
  • Hera BioLabs
  • Ingenious Targeting Laboratory
  • Inotiv
  • Oncodesign Services
  • Ozgene Pty Ltd.
  • Pharmatest Services
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TRANS GENIC
  • TransCure bioServices
  • Vitalstar Biotechnology
Product Code: MRR-961BA04A2E3A

The Humanized Mouse & Rat Model Market was valued at USD 297.24 million in 2025 and is projected to grow to USD 317.57 million in 2026, with a CAGR of 7.54%, reaching USD 494.48 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 297.24 million
Estimated Year [2026] USD 317.57 million
Forecast Year [2032] USD 494.48 million
CAGR (%) 7.54%

An expert overview of how humanized mouse and rat model innovations are reshaping preclinical pipelines and translational research priorities

Humanized mouse and rat models have emerged as indispensable tools in contemporary preclinical research, enabling translational insights across immunology, infectious disease, oncology, neurology, and cardiovascular science. These engineered and patient-derived systems increasingly bridge the chasm between in vitro findings and clinical reality by providing physiologically relevant contexts in which human-specific immune interactions, pathogen tropisms, and tumor biology can be interrogated. As experimental objectives have become more complex, investigators and product developers have demanded higher fidelity models, robust characterization, and integrated service offerings that reduce time to actionable data and enhance reproducibility.

Consequently, suppliers, contract research providers, and academic consortia have expanded their portfolios to include advanced humanized rat variants, a broader range of immunodeficient strains, patient-derived xenograft collections, and precise transgenic constructs. At the same time, improvements in genome editing, breeding, and husbandry, together with enhanced phenotyping and bioassay capabilities, have reshaped how sponsors design preclinical programs. This introduction sets the stage for a deeper analysis of the structural shifts influencing model selection, sourcing strategies, regulatory touchpoints, and end-user preferences, while emphasizing the operational complexities and scientific opportunities that characterize the current landscape.

How advancements in genome engineering, PDX capabilities, and integrated service delivery are redefining translational value and experimental reproducibility

The landscape for humanized rodent models is undergoing transformative shifts driven by converging technological, operational, and scientific forces. First, precision genome engineering and refined immunoengraftment methods have increased the fidelity of humanized immune systems and organ-specific phenotypes, enabling more predictive assessments of immunotherapies and biologics. At the same time, the proliferation of patient-derived xenograft collections and improved cryopreservation practices have accelerated translational oncology programs by preserving tumor heterogeneity and clinical relevance.

Meanwhile, the industry is experiencing a move toward modular service delivery where model provision, efficacy testing, and screening services are bundled to streamline sponsor workflows and reduce administrative friction. Regulatory scrutiny and heightened reproducibility expectations have spurred more rigorous documentation, standardized endpoints, and third-party quality audits. In parallel, computational integration-combining in vivo data with multi-omic readouts and advanced analytics-has emerged as a core capability for unlocking mechanistic insight and optimizing study design. Collectively, these shifts are fostering a more collaborative ecosystem in which cross-disciplinary partnerships, vertical integration, and platform-based approaches define competitive advantage and scientific value.

Assessing how 2025 tariff adjustments shaped supply resilience, procurement strategies, and vendor diversification in preclinical research ecosystems

The cumulative policy adjustments and tariff measures enacted in and around 2025 have exerted a multifaceted impact on supply chains and operational planning for organizations that rely on specialized animal models and contiguous laboratory inputs. For many end users, the immediate effect has been an increase in landed costs for imported breeding stock, specialized consumables, and certain reagents, which has prompted procurement teams to renegotiate supplier agreements, consolidate orders, and prioritize vendors with geographically diversified manufacturing footprints. In response, several providers have adapted by relocating critical production steps, increasing domestic breeding capacity where feasible, and expanding local inventories to buffer against longer lead times.

Beyond direct cost effects, tariffs have influenced decisions about sourcing strategy and vendor selection, reinforcing the importance of contractual flexibility and transparent lead-time commitments. In cases where cross-border logistics became less predictable, sponsors accelerated validation programs for alternative models and suppliers to preserve experimental timelines. Moreover, adjustments in trade policy have elevated compliance requirements and documentation burdens, obliging laboratory and procurement teams to strengthen customs expertise and risk management practices. Taken together, these dynamics have encouraged a shift toward more resilient supply networks, greater emphasis on supplier qualification, and strategic investments in redundancy to protect critical preclinical workflows.

Deep segmentation intelligence revealing how model type, application focus, end-user priorities, and product-service configurations drive procurement and R&D choices

Disaggregating the humanized rodent landscape by model type, application, end user, and product typology reveals targeted strategic implications for R&D planners and procurement leaders. When examined by model type, the market encompasses humanized rat models, immunodeficient models, PDX models, and transgenic models. The humanized rat models category includes hACE2 rat models and hCD4 rat models, which are particularly relevant for viral tropism studies and immuno-oncology investigations respectively. Immunodeficient models further comprise NOG models, NSG models, and SCID models, with variation in engraftment efficiency, immunophenotype, and suitability for diverse xenograft and human immune system reconstitution workflows. Patient-derived xenograft models span breast cancer PDX, colorectal cancer PDX, and lung cancer PDX, offering disease-specific fidelity that supports therapeutic hypothesis testing and biomarker discovery. Transgenic models that are leveraged for mechanistic interrogation and target validation include both knock-in models and knock-out models, each providing distinct advantages for studying gene function and pathway modulation.

Viewed by application, the portfolio aligns with cardiovascular, immunology, infectious disease, neurology, and oncology research needs. Cardiovascular applications include atherosclerosis models and hypertension models that support drug safety and mechanism studies, while immunology applications cover autoimmune disorder models and inflammatory disease models that are critical to biologics development. Infectious disease applications are differentiated into bacterial infection models and viral infection models, a distinction that guides choices around host susceptibility and biosafety. Neurology applications include neurodegenerative disease models and pain models that help translate CNS-targeted therapies, and oncology applications divide into hematological models and solid tumor models depending on tumor microenvironment considerations. End users are typified by academic research institutes, contract research organizations, and pharmaceutical and biotech companies, each adopting different procurement timelines, validation thresholds, and service preferences. Finally, product type distinctions comprise model products and services. Model products are subdivided into commercial models and custom models that address off-the-shelf versus bespoke needs, while services include efficacy testing services, model development services, and screening services that support study execution and translational validation.

Taken together, these segment dimensions indicate that decisions around model selection are increasingly driven by a combination of biological fidelity, service integration, and operational certainty. Sponsors focused on immunotherapies often favor highly characterized immunodeficient strains and tailored humanized constructs, while oncology teams frequently prioritize PDX collections that preserve tumor heterogeneity. Academic institutes are more likely to adopt open-source or academic-sourced models for exploratory work, whereas pharmaceutical and biotech companies emphasize GLP-compliant vendors, reproducible supply chains, and turnkey service packages. Service differentiation-particularly in model development and efficacy testing-has become a principal competitive lever, enabling suppliers to capture longer-term partnerships and reduce transactional friction for complex programs.

Comparative regional analysis detailing how Americas, Europe, Middle East & Africa, and Asia-Pacific differential strengths influence model sourcing, compliance, and service adoption

Regional dynamics shape supply-side capabilities, regulatory interactions, and adoption trajectories for humanized rodent models in distinct ways. In the Americas, a concentration of biotech hubs, strong translational pipelines, and a mature contract research sector support high adoption of advanced humanized constructs and PDX platforms. This region benefits from considerable laboratory infrastructure and a robust service-provider network, which collectively lower barriers to entry for complex in vivo programs, but also face cost pressures related to labor and regulatory compliance. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where pockets of excellence in academic centers and specialized providers coexist with varied regulatory frameworks and reimbursement environments. This diversity yields opportunities for cross-border collaborations and specialized niche services, yet it also requires careful navigation of differing animal welfare standards and import/export regulations.

The Asia-Pacific region has seen rapid capacity expansion in breeding facilities, CRO services, and translational research hubs, coupled with an increasing number of domestically developed model lines and a growing emphasis on local manufacturing of reagents. As a result, this region offers competitive pricing and scale advantages for sponsors pursuing large preclinical programs, though stakeholders should assess supplier quality systems and documentation to ensure alignment with global regulatory expectations. Across all regions, logistical factors, customs processes, and regional policy shifts influence lead times and supplier selection. Consequently, multinational programs often adopt hybrid sourcing strategies that combine local capacity for routine studies with international partners for highly specialized or validated model systems.

Insights into supplier strategies, service integration, proprietary model development, and partnerships that define competitive advantage in preclinical services

Competitive dynamics among suppliers and service providers are characterized by a mix of specialization and consolidation, as firms pursue vertical integration, proprietary model libraries, and value-added service bundles. Leading providers increasingly invest in cryopreserved PDX banks, advanced phenotyping platforms, and proprietary humanization protocols to secure durable client relationships and create technical differentiation. Parallel to this, contract research organizations are expanding their in vivo capabilities through strategic alliances, capacity investments, and the addition of GLP-compliant facilities to support late-stage therapeutic programs.

Innovation is concentrated around improving engraftment efficiency, reducing xenograft variability, and expanding the repertoire of transgenic constructs tailored to specific mechanistic questions. Providers that excel in quality systems, traceability, and regulatory documentation have a competitive advantage when engaging with large pharmaceutical sponsors who require stringent supplier qualification. In addition, service models that integrate model development, efficacy testing, and biomarker readouts enable suppliers to move up the value chain and capture a greater share of sponsor spend. Finally, partnerships with academic centers and hospital networks are becoming more common, facilitating access to fresh tumor specimens for PDX generation and enabling translational collaborations that accelerate target validation and clinical translation.

Actionable strategic steps leaders should implement to enhance supplier resilience, translational validity, regulatory readiness, and service integration

Industry leaders can adopt a set of pragmatic actions to strengthen operational resilience, scientific rigor, and commercial positioning in the evolving humanized rodent ecosystem. First, prioritize supplier qualification processes that include documentation of breeding records, genetic validation, and engraftment performance, and integrate those criteria into long-term procurement agreements to reduce variability. Second, invest in dual-sourcing strategies and regional redundancy for critical models and reagents in order to mitigate disruptions from policy shifts or logistics constraints, thereby preserving study timelines.

Third, foster internal capabilities for translational assay development and data harmonization so that in vivo findings can be more readily integrated with multi-omic and imaging readouts, increasing the predictive value of preclinical programs. Fourth, negotiate service-level commitments with CRO partners that include clearly defined timelines, contingency plans, and mutual performance metrics to align incentives and reduce downstream delays. Fifth, accelerate the adoption of standardized reporting formats and metadata frameworks across studies to enhance reproducibility and facilitate regulatory engagement. Sixth, pursue strategic collaborations with clinical centers and biobanks to expand access to diverse PDX sources and to enrich translational relevance. Seventh, allocate resources to continuous staff training on animal welfare, biosafety, and regulatory compliance to ensure ethical and high-quality study conduct. Finally, evaluate commercialization opportunities for proprietary models and platform services, balancing licensing potential with the operational demands of scale and quality assurance.

A transparent, triangulated research approach combining expert interviews, documentary analysis, and validation checks to produce reliable strategic insights for stakeholders

The research methodology underpinning this analysis combined structured primary inquiry, rigorous secondary review, and iterative validation to ensure the findings are robust and actionable. Primary inputs included interviews with scientific leaders, procurement managers, and CRO executives to capture real-world decision criteria, lead-time sensitivities, and evolving service expectations. Secondary review encompassed peer-reviewed literature, regulatory guidance documents, technical product literature, and operational reports to map technological trajectories and quality standards. These qualitative and documentary inputs were synthesized to develop a segmentation framework, scenario analyses for supply-chain impacts, and comparative regional assessments.

To validate conclusions, triangulation was employed through cross-referencing interview insights with supplier literature and operational performance indicators, and follow-up consultations were conducted to reconcile divergent perspectives. Quality control procedures included standardized interview guides, source attribution logs, and a reproducibility checklist that documented key assumptions. The methodology acknowledges limitations tied to proprietary supplier data and the rapidly changing policy environment; as such, readers are encouraged to treat the insights as strategic guidance that should be augmented with firm-specific due diligence when making procurement or R&D decisions.

Final synthesis emphasizing why integration of scientific fidelity, supplier qualification, and operational resilience is essential for translational success

In conclusion, humanized mouse and rat models represent a vital nexus between experimental biology and clinical translation, with ongoing innovations in genetic engineering, PDX preservation, and integrated service delivery redefining preclinical strategy. The interplay of technological progress, regulatory expectations, and supply-chain dynamics requires sponsors to adopt more sophisticated procurement, qualification, and collaboration practices. As tariff and policy environments evolve, organizations that invest in supplier diversification, rigorous documentation, and translational assay integration will be better positioned to sustain program momentum and extract higher predictive value from in vivo studies.

Ultimately, the competitive landscape rewards those who combine scientific excellence with operational discipline: firms that can deliver reproducible, well-characterized models alongside turnkey services will capture deeper sponsor engagement and support faster decision making. By applying the segmentation insights, regional considerations, and actionable recommendations provided herein, stakeholders can align their preclinical strategies with scientific priorities and operational realities to accelerate therapeutic development and mitigate risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Humanized Mouse & Rat Model Market, by Model Type

  • 8.1. Humanized Rat Models
    • 8.1.1. hACE2 Rat Models
    • 8.1.2. hCD4 Rat Models
  • 8.2. Immunodeficient Models
    • 8.2.1. NOG Models
    • 8.2.2. NSG Models
    • 8.2.3. SCID Models
  • 8.3. PDX Models
    • 8.3.1. Breast Cancer PDX
    • 8.3.2. Colorectal Cancer PDX
    • 8.3.3. Lung Cancer PDX
  • 8.4. Transgenic Models
    • 8.4.1. Knock-In Models
    • 8.4.2. Knock-Out Models

9. Humanized Mouse & Rat Model Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis Models
    • 9.1.2. Hypertension Models
  • 9.2. Immunology
    • 9.2.1. Autoimmune Disorder Models
    • 9.2.2. Inflammatory Disease Models
  • 9.3. Infectious Disease
    • 9.3.1. Bacterial Infection Models
    • 9.3.2. Viral Infection Models
  • 9.4. Oncology
  • 9.5. Cell Therapy Testing

10. Humanized Mouse & Rat Model Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech Companies

11. Humanized Mouse & Rat Model Market, by Human Cell

  • 11.1. CD34+ Stem Cells
  • 11.2. PBMC
  • 11.3. Patient Tumor Tissue (PDX)
  • 11.4. iPSC-derived Cells

12. Humanized Mouse & Rat Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Humanized Mouse & Rat Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Humanized Mouse & Rat Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Humanized Mouse & Rat Model Market

16. China Humanized Mouse & Rat Model Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aragen Life Sciences Ltd.
  • 17.6. Biocytogen
  • 17.7. Champions Oncology, Inc.
  • 17.8. Charles River Laboratories
  • 17.9. Crown Biosciences
  • 17.10. Cyagen Biosciences
  • 17.11. GemPharmatech
  • 17.12. genOway
  • 17.13. Harbour BioMed
  • 17.14. Hera BioLabs
  • 17.15. Ingenious Targeting Laboratory
  • 17.16. Inotiv
  • 17.17. Oncodesign Services
  • 17.18. Ozgene Pty Ltd.
  • 17.19. Pharmatest Services
  • 17.20. Taconic Biosciences, Inc.
  • 17.21. The Jackson Laboratory
  • 17.22. TRANS GENIC
  • 17.23. TransCure bioServices
  • 17.24. Vitalstar Biotechnology

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL THERAPY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CD34+ STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PBMC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PATIENT TUMOR TISSUE (PDX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IPSC-DERIVED CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 263. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 275. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)